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Abstract 
Background: Recommended regimens for HIV-positive individuals include the co-administration of dolutegravir 
(DTG) with two reverse transcriptase inhibitors (RTIs). Although rare, emerging resistance against DTG is often associ-
ated with the R263K substitution in integrase. In-vitro-selected R263K was associated with impaired viral replication 
capacity, DNA integration, and integrase strand-transfer activity, especially when accompanied by the secondary 
mutation H51Y. Given the reduced fitness of RTI-resistant viruses, we investigated potential impacts on viral replica-
tion of combining R263K and H51Y/R263K with major RTI-resistance substitutions including K65R, L74V, K103N, E138K, 
and M184I/V.
Results: We combined the R263K or H51Y/R263K with RTI-resistance mutations into the proviral plasmid pNL4.3 and 
measured the resulting viral infectiousness, replication capacity, and ability to integrate viral DNA into host cells. Infec-
tiousness was determined by luciferase assay in TZM-bl cells. Replicative capacity was monitored over 7 days and viral 
DNA integration was studied by real-time Alu-qPCR in PM1 cells. We found that viral infectiousness, replication capaci-
ties and integration levels were greatly reduced in triple mutants, i.e. H51Y/R263K plus a RT mutation, and moderately 
reduced in double mutants, i.e. R263K plus a RT mutation, compared to wild-type and single RT-mutant viruses.
Conclusions: Our findings help to explain the absence of RTI mutations in individuals who experienced DTG-treat-
ment failure.
Keywords: HIV-1, Integrase, Viral replication, Integrase inhibitors, R263K, H51Y, Reverse transcriptase inhibitors, K65R, 
L74V, K103N, E138K and M184V/I
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Background
Current antiretroviral (ARV) drugs for treatment of 
human immunodeficiency virus (HIV) infection include 
entry inhibitors, protease inhibitors (PIs), nucleoside/
non-nucleoside reverse-transcriptase inhibitors (NRTIs/
NNRTIs) and integrase strand-transfer inhibitors 
(INSTIs). In the later class, dolutegravir (DTG) is the 
most potent drug and can be used without a boosting 
agent [1]. Unlike raltegravir (RAL) and elvitegravir (EVG), 
DTG has a higher barrier to resistance, and minimal 
drug–drug interactions [1, 2]. First-line treatment failure 
in patients receiving a once daily dose of 50 mg of DTG 
seems mainly due to non-adherence. Emergence of drug 
resistance against DTG has not been observed after first-
line therapy [3–5]. In second-line treatment of INSTI-
naïve patients, a R263K mutation commonly emerged 
but this substitution causes only about a twofold change 
in IC50, suggesting that the impact on DTG susceptibility 
is very low. The absence of clinical impact of the R263K 
mutation has meant that patients harbouring this substi-
tution might be able to remain on DTG therapy [1, 6].
We previously showed that R263K-containing viruses 
possess modestly reduced viral replication capacity 
(about 70 % compared to WT) [7, 8]. The R263K substi-
tution was also selected in vitro, and this was followed by 
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the appearance of such secondary substitutions as H51Y, 
M50I, and E138K [7–10]. However, none of the lat-
ter could compensate for the loss in replicative capacity 
conferred by R263K and, in fact, had the effect of further 
decreasing viral replication, integrase strand-transfer 
activity and levels of integrated DNA, even though the 
addition of H51Y to R263K increased resistance to DTG 
to about sevenfold, as measured by the PhenoSense® 
Integrase Replication Assay (7–10). Similar impacts on 
viral replicative capacity and DTG resistance in tissue 
culture and biochemical assays were observed when the 
E138K or M50I substitutions were introduced into R263K 
viruses. The H51Y/R263K and M50I/R263K viruses may 
confer similar levels of DTG resistance (about sevenfold 
resistance against DTG as measured in TZM-bl cells by 
luciferase assay) while the level of resistance is only about 
4.3-fold for the E138K/R263K virus [7, 8, 10].
This is in contrast to the RAL and EVG resistance path-
ways, in which secondary mutations commonly restored 
viral replication capacity while, at the same time, add-
ing to the level of drug resistance conferred by initially 
selected mutations [11–13]. The absence of compensa-
tory secondary mutations for R263K is also consistent 
with the observation that many major RAL- and EVG-
resistance substitutions such as G140S, Q148R, E92Q, 
N155H and Y143R are incompatible with the simultane-
ous presence of R263K in terms of both integrase strand-
transfer activity and viral replication capacity [14]. In 
addition, the emergence of R263K as a secondary substi-
tution has been documented in tissue culture under EVG 
selection pressure as well as in a Phase two clinical trial 
of the antiviral activity of EVG [15]. More recently, we 
have shown that the T66I/R263K combination severely 
impaired both integrase strand-transfer activity and viral 
replicative capacity. The T66I/R263K virus was slightly 
more susceptible to DTG when viruses containing R263K 
alone were studied but highly resistant to EVG, which 
explains the emergence of this combination with EVG 
but not DTG [15].
DTG is commonly used in treatment together with 
abacavir/lamivudine (ABC/3TC) or tenofovir/emtric-
itabine (TDF/FTC) in ARV-naïve patients. However, 
the combined effects of DTG- and RT-resistance muta-
tions have not been well studied until now, although it is 
known that the combination of M184I/V and R263K in 
the same virus further decreased viral replication com-
pared to either mutation alone and no DTG or lamivu-
dine cross-class resistance was observed [16]. Now, we 
have studied the effect of R263K or H51Y-R263K in the 
presence of other clinically relevant RT mutations, i.e. 
K65R, L74V, K103N, E138K, and M184I/V. Of the above, 
K103N is a major mutation associated with resistance 
to efavirenz and etravirine; both NNRTIs are known to 
reduce plasma levels of DTG, thereby limiting their use 
in co-administration with DTG [17, 18]. The E138K sub-
stitution in RT has been selected in patients treated with 
rilpivirine and efavirenz and has resulted in cross-resist-
ance to NNRTIs. Each of K65R, L74V and M184I/V are 
major NRTI-related mutations [17, 18]. Tenofovir, ABC, 
lamivudine and didanosine can select for K65R, while 
lamivudine and emtricitabine select for M184I/V. In the 
phase 3 102 and 103 clinical studies of a once daily pill of 
EVG/cobicistat/FTC/TFV, the K65R and M184I/V sub-
stitutions were detected, separately or in combination, 
before the emergence of IN mutations in some patients 
undergoing treatment failure [19, 20]. L74V has been 
selected by didanosine and ABC and can confer high-
level resistance against these drugs [17, 18].
Results
The addition of DTG‑resistance substitutions reduces 
viral infectiousness in viruses containing the K65R, L74V, 
K103N, E138K or M184V/I reverse transcriptase mutations
As previously hypothesized, the fitness cost of the H5Y/
R263K combination may have a benefit for patients 
under DTG treatment in terms of viral load. Given the 
current co-administration of DTG with RTIs for HIV 
treatment, we wanted to determine whether the R263K 
and H51Y/R263K mutations may have similar effects on 
viruses that contained mutations in RT that confer resist-
ance to RTIs. First, we created chimeric HIVs having 
R263K or both H51Y/R263K in IN together with any of a 
number of major RTI-resistance substitutions, i.e. K65R, 
L74V, K103N, E138K, or M184I/V. We then performed 
single round infections in TZM-bl cells and measured 
levels of luciferase expression after 48 h.p.i.; these levels 
were normalized on the basis of p24 expression. Levels 
of viral infectivity were determined for each of the vari-
ous DTG-resistant and RTI-resistant viruses and those 
containing only a single RT mutation in the absence of 
drugs. Our results show that the addition of R263K to the 
K65R-, L74V-, K103N-, E138K-, or M184I/V-harbouring 
viruses resulted in further moderate decreases in viral 
infectivity ranging from 1.23-fold to 3.17-fold (P < 0.05), 
depending on the RT backbone (Fig.  1a–f). In viruses 
carrying K65R, E138K, or M184V, the additional pres-
ence of R263K in IN coding sequence caused a further 
impact on viral replication than was associated with any 
of these RT mutations on their own. These data are con-
sistent with previous findings that reported that the pres-
ence of R263K in combination with M184I/V resulted in 
a further 1.8-fold decrease in replication capacity com-
pared to M184I or M184V alone [16]. The most nega-
tive impact observed was when R263K was combined 
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with E138K, yielding a 3.2-fold decrease in infectiousness 
compared to E138K alone (Fig.  1d), whereas only slight 
decreases, about 1.2-fold were observed for R263K-L74V 
(Fig. 1b) and 1.3-fold for R263K-K103N (Fig. 1c) viruses 
compared to L74V and K103N alone, respectively.
The RT mutant viruses that also carried the inte-
grase double mutations, i.e. H51Y/R263K were very 
impaired in replication (P  <  0.05), i.e. a 3.36-fold–10.4-
fold decrease compared to the single RT mutations 
alone (Fig.  1a–f). The order of diminished infectious-
ness with H51Y/R263K was as follows: E138K, relative 
fold-change (FC) = 10.4 (Fig. 1d), K65R with FC = 7.88 
(Fig.  1a), M184V with FC  =  7.71 (Fig.  1f ), and M184I 
with FC =  6.25 (Fig.  1e). The addition of double muta-
tions H51Y/R263K to the L74V or K103N viruses also 
affected viral replication but at lower levels, i.e. 3.36 and 
3.70 FC (Fig. 1b, c). R263K on its own together with any 
one of the RT mutations in the same virus yielded only 
slight reductions in viral infectivity compared to either 
mutation alone, and the presence of both H51Y/R263K 
together with the RT mutations had the most severe con-
sequence on infectiousness. We also conducted RT assays 
to validate our p24 results and found that a comparison 
of results from RT and p24 assays yielded similar findings 
for WT or viruses containing the R263K or H51Y/R263K 
substitutions (Table  1), but not for viruses containing 
mutations in the RT sequence (data not shown).
Combining DTG‑ and RTI‑resistance mutations reduces 
viral replicative capacity
Next we infected PM1 cells with our various viruses 
in the absence of drugs using the same quantity of p24 
antigen in each case over a 7-day period and harvested 
virus-containing cell culture fluids at days 3 and 7 p.i. 
for p24 measurements. At day 3 p.i., we obtained detect-
able levels of p24 with both the WT and single RT 
mutation viruses, showing that these viruses began to 
replicate very early; the p24 levels continued to increase 
over 7 days (Fig. 2a–f). In contrast, none of the R263K-
containing viruses produced detectable p24 in our assay 
until day 7 p.i. (Fig. 2a–f). However, the viruses that con-
tained H51Y/R263K plus a RT mutation or only H51Y/
R263K were unable to generate detectable p24 at day 7, 
suggesting that significant replication had not occurred 
(Fig.  2a–f). These results from replication kinetics over 
a 7-day period of infection lend support to the observa-
tion that the presence of R263K or H51Y/R263K in the 
IN sequence together with K65R, L74V, K103N, E138K, 
or M184V/I in the same virus resulted in slight to signifi-
cant decreases in viral replication capacity (Fig. 1a–f). In 
both experiments, the L74V and K103N viruses were the 
least affected by the presence of H51Y/R263K or R263K.
Integration capacity of DTG‑ and RTI‑resistant viruses
We next wished to determine whether the integration 
efficiency of the viruses containing the various combina-
tions discussed above might be diminished in tissue cul-
ture. For each virus, we used the same amount of p24 to 
infect PM1 cells and harvested infected cells after 2 days. 
Total DNA was extracted and Alu-mediated qPCR was 
performed to quantify integration levels of HIV-1 DNA 
into PM1 cells. The results show that all the RTI-resist-
ant viruses that also contained R263K exhibited slightly 
decreased levels of viral integration capacity, about 0.1 
log–0.5 log reduction, compared to the single RT muta-
tion viruses and WT (Fig.  3a–f). However, these differ-
ences were not statistically significant (all P values >0.05, 
Fig.  3a, c, d, f ), except for L74V versus R263K-L74V 
(P  =  0.03, Fig.  3b) and M184I versus R263K-M184I 
(P = 0.05, Fig. 3e). Results from the Alu-mediated qPCR 
studies of viruses containing H51Y/R263K showed low 
levels of integrated DNA in cases of these viruses H51Y/
R263K-K65R, H51Y/R263K-L74V and H51Y/R263K-
M184V (Fig.  3a, b, f ), or undetectable levels in H51Y/
R263K-K103N, H51Y/R263K-E138K and H51Y/R263K-
M184I viruses (Fig. 3c–e) in comparison to those of sin-
gle RT mutants and WT virus (P values with statistical 
significance are shown in Fig.  3a, b, f ), consistent with 
the viral replication data discussed above [8, 9]. However, 
this trend did not reach statistical significance for the 
K65R versus H51Y/R263K-K65R viruses (P = 0.08).
Discussion
Current HIV treatment guidelines for first line therapy 
favor the use of an INSTI together with two NRTIs. 
In treatments based on the use of RAL or EVG, the 
(See figure on previous page.) 
Fig. 1 Effects of R263K and H51Y/R263K in combination with different RTI substitutions on viral infectivity in TZM-bl reporter cells. Expressed luciferase 
levels were measured at 48 h.p.i. and normalized to relative p24 levels. Best-fit curves and data for EC50 values, 95 % confidence intervals and fold 
changes (FC) relative to single RT mutations alone are showed in the insets: a K65R series including NL4.3K65R, NL4.3R263K-K65R, and NL4.3H51Y/R263K-K65R. b 
L74V series including NL4.3L74V, NL4.3R263K-L74V, and NL4.3H51Y/R263K-L74V. c K103N series including NL4.3K103N, NL4.3R263K-K103N, and NL4.3H51Y/R263K-K103N. d 
E138K series including NL4.3E138K, NL4.3R263K-E138K, and NL4.3H51Y/R263K-E138K. e M184I series including NL4.3M184I, NL4.3R263K-M184I, and NL4.3H51Y/R263K-M184I. 
f M184V series including NL4.3M184V, NL4.3R263K-M184V, and NL4.3H51Y/R263K-M184V. The FC value of each singly mutated RT virus was arbitrarily set at 1. Error 
bars indicate mean ± standard deviation (SD). Asterisk and dollar sign indicate statistically significant difference from single RT mutants alone and from 
the R263K-containing viruses, respectively (Student’s t test, P < 0.05)
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co-existence of NRTI and INSTI resistance mutations 
has been reported in patients experiencing therapeutic 
failure [19–21]. Most commonly, mutations at N155H 
and Q148H/R have been observed in combination with 
M184I/V or less often with K65R. In some of these 
cases, both K65R and M184V/I have co-emerged with 
integrase mutations. Fitness defects were also observed 
for viruses containing these RAL/EVG-resistance muta-
tions together with RT mutations in vitro in the absence 
of drugs [22, 23]. In contrast, neither DTG nor NRTI 
resistance has been reported until now in treatment-
naïve patients who received DTG plus NRTI treatment. 
Given that the R263K substitution has been reported 
in some INSTI-naïve patients in the SAILING study 
and in tissue culture selections, we aimed to investigate 
the effects of R263K and its secondary mutation H51Y 
together with major RTI-resistance substitutions at 
positions K65R, L74V, K103N, E138K, and M184I/V, in 
terms of viral replication and integration capacity in the 
absence of drugs.
Table 1 Comparison of RT and p24 assays for normalization of viral infectivity in TZM-bl cells
*,$  Statistically significant difference from WT and R263K viruses, respectively (Student’s t test, P < 0.05)
Genotype p24 assay RT assay
EC50  
(ng p24)










WT 3.57 1 2.77–4.58 3270 1 2545–4200
R263K 4.64 1.3* 3.68–5.84 3864 1.2* 3067–4868
H51Y/R263K 27.12 7.6*,$ 24.65–29.18 22,964 7*,$ 20,870–25,269
          K65R    ba c
ed f
          L74V          K103N































































Fig. 2 Viral replication kinetics over a 7-day period in PM1 cells. PM1 cells were infected with the same amount of p24 for all viral stocks. Levels of 
p24 production in cell-free supernatants were monitored at days 3 and 7 p.i. WT, R263K and H51Y/R263K viruses are also presented in each data 
series from a to f. a K65R series, b L74V series, c K103N series, d E138K series, e M184I series, and f M184V series. Values were calculated from three 
independent infections. Error bars indicate mean ± SD. ND not detectable
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First, our study confirmed previous observations on the 
decrease of viral replication in viruses containing both 
M184I/V plus R263K [16]. We also confirmed the defi-
cits caused by R263K together with other RTI mutations, 
i.e. K65R, L74V, K103N, and E138K. However, small 
changes in the results of infectivity assays may or may not 
result in differences in infectivity in  vivo. Compared to 
WT virus, the R263K substitution as well as some other 
major mutations E92Q, Q148R and N155H, reported in 
the RAL- and/or EVG-resistance pathways, can emerge 
from a single nucleotide change in most HIV-1 strains. 
Each of these mutations led to a decrease in viral repli-
cative fitness (less than sevenfold) and integrase strand-
transfer activity (less than threefold). However, the levels 
of resistance associated with these various substitutions 
for different INSTIs varied considerably. For example, 
N155H virus caused sixfold and fivefold decreases in sus-
ceptibility to RAL and EVG and E92Q conferred more 
than a 50-fold decrease in EVG susceptibility. Similar six-
fold–sevenfold levels of resistance to RAL and EVG have 
been reported for Q148R virus [14]. In contrast, the com-
mon M184V mutation develops rapidly in patients fail-
ing lamivudine (3TC) therapy. Although this mutation 
alone confers up to 100-fold–1000-fold less susceptibility 
to 3TC, regimens containing this drug have been shown 
to maintain efficacy in the treatment of HIV-1, perhaps 
because the M184V mutation is associated with a loss 
of replicative fitness and increased fidelity of RT activity 
[24]. Nevertheless, the combination of M184V with K65R 
has caused virological failures in patients receiving regi-
mens containing two N(t)RTIs, 3TC and tenofovir [25].
On the other hand, R263K is more commonly detected 
in HIV-positive individuals who experience treatment 
failure with DTG even though this substitution only 
modestly decreases DTG susceptibility (about twofold) as 
well as HIV-1 replication capacity. This raises the ques-
tion as to why this substitution is not more commonly 
observed in clinical settings since its effect on viral fit-
ness is insufficient on its own to explain its absence 
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Fig. 3 Integrated HIV DNA levels in PM1 cells at day 2 p.i. were measured by Alu-mediated qPCR assays (presented on a log scale). Error bars indicate 
mean ± SD. a K65R series, b L74V series, c K103N series, d E138K series, e M184I series, and f M184V series. Only P values with statistic significance 
were showed. The levels of integration are relative to WT virus at 0 h post infection. ND not detectable
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possibility is that viruses that contain R263K and other 
resistance mutations, e.g. H51Y, are so impaired in repli-
cation capacity that they cannot be detected by ordinary 
Sanger sequencing. Another possibility is that DTG may 
reach anatomical compartments that are not susceptible 
to other inhibitors, effectively preventing the emergence 
of R263K and other substitutions; this possibility is sup-
ported by recent reports of persistent HIV replication 
under suppressive ARV therapy [1, 26].
A related question is why the R263K substitution that 
confers low-level resistance to DTG is selected at all. The 
answer is probably that R263K does confer a higher level 
of resistance against DTG as a single substitution than 
does any of the resistance mutations associated with RAL 
or EVG (1). This is fortuitous for the use of DTG even 
in patients who are not adherent to therapy, especially 
because the R263K substitution does not seem to be able 
to co-exist together with mutations at positions 143 and 
148 that are frequently observed in patients who have 
failed therapy with RAL or EVG (14). Secondary resist-
ance mutations usually follow after primary mutations 
and can both compensate for the loss of viral replica-
tion caused by the initial mutation while also resulting in 
higher levels of drug resistance [1]. However, no second-
ary mutation for DTG can compensate in this fashion [7, 
8, 10]. We previously demonstrated that the secondary 
mutation H51Y developed after the emergence of R263K 
in  vitro and caused a higher level of resistance against 
DTG, about 16-fold in TZM-bl cells and sevenfold in the 
PhenoSense® Integrase Replication assay. H51Y also has 
a further detrimental effect on viral replication capacity. 
The current study also shows that this replication defi-
cit is further exacerbated in the presence of different RT 
resistance mutations, helping to explain the absence of 
resistance to both DTG and RTIs in first-line therapy.
K103N is a very common NNRTI mutation that only 
minimally affects viral replication in the absence of 
drug pressure [27, 28]. The addition of R263K to K103N 
caused only a small loss in viral replication capacity com-
pared to K103N alone. L74V is associated with a reduced 
replicative capacity of HIV-1 of about 11 % compared to 
WT [29, 30]. In our study, decreased replication was also 
observed with the R263K-L74V virus and this was greatly 
exacerbated by the additional presence of H51Y. Similar 
results were obtained with K103N together with R263K/
H51Y, with no detection of p24 at days 3 and 7 p.i. Our 
data show that differences in viral replication in the pres-
ence of different resistance mutation combinations may 
not only be due to possible additive effects but may also 
reflect possible interactions between RTI- and DTG-
resistance mutations. The addition of R263K to viruses 
containing M184I or M184V, K65R, and E138K yielded 
fewer viruses that were replication competent than when 
only single RT mutations were studied. And these differ-
ences were further magnified in the presence of H51Y. 
Possibly as well, the presence of some triple combina-
tion mutations may alter interactions between RT and 
IN, leading to a loss of viral replication and/or generation 
of non-viable viruses. In the presence of drug pressure, 
it may be very difficult for HIV-1 to develop all of these 
mutations in IN and RT at the same time. These findings 
are consistent with earlier results that the emergence of 
M184I was delayed in the presence of R263K under lami-
vudine drug pressure and that the M184I substitution 
was detected in the case of the H51Y/R263K virus [31].
Here we also report on the integration capacity of the 
mutational combinations studied in PM1 cells in com-
parison to that of WT virus and viruses containing only 
single RT mutations. Double mutant viruses with RT and 
R263K integrated less efficiently than either viruses with 
single RT mutations or WT whereas DNA integration 
levels in almost all triple mutant viruses were very low or 
undetectable. Although small differences in integration 
levels were observed for single RT mutants and double 
R263K-RT mutants, these were not significant (Student’s 
t test, P values >0.05), whereas statistical significance was 
achieved for L74V versus R263K-L74V (Student’s t test, 
P  =  0.03) and M184I versus R263K-M184I (Student’s 
t test, P = 0.05). In addition, triple mutants bearing the 
H51Y/R263K-RT mutations resulted in either undetecta-
ble integration levels (in cases of H51Y/R263K plus single 
substitutions K103N, E138K or M184I, Fig. 3c–e) or lev-
els of integration that were statistically inferior to those 
attained with the single RT mutants (P ≤ 0.05). L74V and 
M184I are associated with resistance against ABC, which 
is co-formulated with DTG and lamivudine in a single 
daily pill; these results suggest that this combination may 
provide an advantage in regard to pathways leading to 
drug resistance.
Our integration data, however, did not always directly 
correlate with the infectivity data (Fig. 1a). For example, 
H51Y/R263K-K65R triple mutants resulted in appre-
ciable levels of integration that were comparable with 
those observed with the double mutant R263K-K65R 
virus (Student’s t test, P = 0.2), whereas the same H51Y/
R263K-K65R combination of substitutions attenuated 
infectivity by 7.8-fold compared to the R263K-K65R com-
bination that only caused a 1.7-fold decrease (Fig.  1a). 
Although both assays demonstrated a tendency for the 
triple mutants to be more impaired in both integration 
and infectivity than the double mutants, some discrepan-
cies in the extent of the impairment as measured in these 
various assays clearly exist. This may be due to the fact 
that integration levels were measured using a single viral 
inoculum whereas the infectivity assays used virus at var-
ious titers. In addition, there may be differences between 
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the susceptibilities of different cell lines to becoming 
infected by the different viruses that were employed. 
Indeed, integration was necessarily measured in PM1 
cells, which support productive HIV-1 replication, 
whereas the TZM-bl cells used in the infectivity assay 
do not support multiple cycles of active replication. It is 
well established that different methods can yield different 
results in regard to infectivity and resistance assays [8].
Since integration is important for virus to establish 
latent reservoirs in host cells, we conjecture that the 
diminution in levels of integration associated with resist-
ance to DTG may have consequences for the size of the 
viral reservoir. Further studies on the capacity of latency 
reservoirs to be established in patients with DTG-resist-
ant viruses or in patients treated with DTG will provide 
important information on long-term DTG treatment effi-
cacy [1].
Conclusions
DTG- and RTI-containing viruses are associated with sig-
nificant loss of viral fitness and DNA integration capacity. 
This could help to explain the successful use of DTG in 
treatment of HIV in co-administration with two-NRTI 
backbones ABC/TDF or FTC/TDF. Our results provide 
additional information to explain the absence of clinically 




TZM-bl and 293T cells were cultured in Dulbecco’s Mod-
ified Eagle Medium (DMEM). PM1 cells were cultured in 
Roswell Park Memorial Institute Medium (RPMI). Cell 
culture media were supplemented with 10 % fetal bovine 
serum (FBS), 2 mM l-glutamine, 50 U/ml penicillin, and 
50 µg/ml streptomycin and incubated at 37 °C under 5 % 
CO2.
Generation of infectious HIV‑1 stocks
pNL4.3, pNL43R263K, pNL4.3H51Y/R263K, pNL4.3M184I, 
pNL4.3M184V, pNL4.3R263K-M184I, pNL4.3R263K-M184V, 
pNL4.3K65R, pNL4.3L74V, pNL4.3K103N, and pNL4.3E138K 
were previously constructed using site-directed mutagene-
sis [16, 32, 33]. Similar methods were employed to produce 
these plasmids: pNL4.3R263K-K65R, pNL4.3H51Y/R263K-K65R, 
pNL4.3R263K/L74V, pNL4.3H51Y-R263K/L74V, pNL4.3R263K-K103N, 
pNL4.3H51Y/R263K-K103N, pNL4.3R263K-E138K, pNL4.3H51Y/
R263K-E138K, pNL4.3H51Y/R263K-M184I, and pNL4.3H51Y/R263K-
M184V. The primer sequences used for PCR site-directed 
mutagenesis were previously described [8, 9]. All clones 
that were generated after transformation were purified 
and sequenced to confirm the presence of expected muta-
tions and have no contamination. To produce infectious 
homogenous viruses, 12.5  µg of each plasmid DNA puri-
fied from maxi cultures that were themselves initiated 
from a single bacterial clone was transfected into 293T cells 
using Lipofectamine 2000 (Invitrogen). Fresh medium was 
added at 4 h.p.i. Culture supernatants containing single 
cycle HIV virions were collected at 48 h post transfection 
and passed through a 0.45-µm filter. Virus stocks were ali-
quoted into small volumes of 500 µl and stored at −80 °C. 
Freshly thawed virus stocks were used for every experiment 
and virus stocks left after each usage were discarded and 
never used again. Quantification of viruses was performed 
using p24 and RT assays as described previously [8, 9].
HIV‑1 infectivity assay
HIV-1 infectivity studies were performed by luciferase 
assay and by short-term infection of TZM-bl reporter 
cells. Thirty thousand TZM-bl cells/well were infected 
with a series of diluted viruses in a 96-well flat-bottom 
plate. Cells were lysed with Promega lysis buffer at 48 
h.p.i. Luciferase levels were measured using the Lucif-
erase Assay System (Promega, Madison, WI, USA). 
Experiments were performed in triplicate and repeated 
twice. Fold changes in the decreases of infectivity (FC) 
were represented as relative EC50, which is the amount 
of virus (previously quantified using p24 and RT assays) 
needed for TZM-bl cells to produce half of the maximal 
level of luciferase in an infection.
Replication capacity assay
Thirty thousand PM1 cells were infected with 18  ng 
of p24 for each virus. Briefly, cells were incubated with 
viruses for 1  h at 37  °C. After incubation, cells were 
washed to remove unbound viruses and seeded in 
96-well plates. Cell-free medium containing viruses was 
withdrawn for p24 measurements at days 3 and 7 p.i. The 
same volumes of fresh medium and new cells were added 
at each time point. Experiments were done in triplicate 
and each study of RT mutated viruses was performed 
separately.
Determination of integrated‑HIV DNA
A total of 2 ×  105 PM1 cells were infected with 125 ng 
p24. Cellular DNA was extracted at 48 h.p.i., using a 
DNeasy blood and tissue kit (Qiagene). A two-step Alu-
gag PCR was performed as previously described [34]. 
The first-round PCR was performed with a 65  ng DNA 
sample in a 25 µl reaction with primers Alu-F: 5′-GCCTC 
CCAAAGTGCTGGGATTACAG-3′ and Gag-R: 
5′-GTTCCTGCTATGTCACTTCC-3′. The first cycle 
conditions were: 95  °C for 2  min, followed by 40 cycles 
of 95  °C for 15  s, 50  °C for 15  s, 72  °C for 3  min 30  s, 
and final elongation was at 72 °C for 5 min. The second-
nested PCR was performed on a Corbett Rotor-Gene 
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6000 thermocycler, using Platinum quantitative PCR 
(qPCR) SuperMix-UDG (Invitrogen) with 5  µl of first-
round PCR product in a 20  µl reaction. The primer 
sequences were LTR-F: TTAAGCCTCAATAAAGCTTG 
CC and LTR-R: GTTCGGGCGCCACTGCTAGA with 
the following cycle conditions: 50  °C for 2  min, 95  °C 
for 2 min, 60 cycles of 95 °C for 10 s, 60 °C for 10 s and 
72  °C for 45 s. All samples were normalized in terms of 
β-globin content. The levels of integration are relative to 
WT virus at 0 h post infection.
Statistical analyses
Each experiment was repeated twice using three repli-
cate samples each time. Data analyses including linear 
and non-linear regressions, and determinations of EC50, 
standard deviation, 95  % confidence intervals, and rela-
tive FC were calculated using GraphPad Prism 5.0 soft-
ware. We used two-tailed Student’s t test with a 0.05 
cut-off point to compare the best-fit values or means of 
each pair of different data sets.
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